Eyeing emerging markets, Abbott nabs Zydus Cadila deal

Abbott Laboratories (NYSE: ABT) says it has entered into a licensing agreement to commercialize products of India's Zydus Cadila in 15 emerging markets in a bid to accelerate Abbott's growth in those areas; the company also set up a business unit to concentrate on the developing world. Release | Report

Suggested Articles

The eight-year deal will initially cover lupus drug Benlysta and could expand to other GSK specialty-care products in the future.

Amarin had big plans for Vascepa after a big label expansion last year, but it lost a patent fight—and now a generic has won FDA approval.

Intercept Pharmaceuticals, eager to market its potential nonalcoholic steatohepatitis medicine obeticholic acid, will have to keep waiting.